{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:45:31Z","timestamp":1790793931962,"version":"4.1.0"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.neuropharm.2016.04.044","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T09:58:12Z","timestamp":1462096692000},"page":"180-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["The impact of metabotropic glutamate receptors into active neurodegenerative processes: A \u201cdark side\u201d in the development of new symptomatic treatments for neurologic and psychiatric disorders"],"prefix":"10.1016","volume":"115","author":[{"given":"Valeria","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-6054","authenticated-orcid":false,"given":"Filippo","family":"Caraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-2590","authenticated-orcid":false,"given":"Agata","family":"Copani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Matrisciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.04.044_bib1","doi-asserted-by":"crossref","first-page":"64e70","DOI":"10.1016\/j.pscychresns.2009.07.007","article-title":"Voxel-based analyses of gray\/white matter volume and diffusion tensor data in major depression","volume":"181","author":"Abe","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2014.12.069","article-title":"Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis","volume":"226","author":"Ahmed","year":"2015","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.neuroscience.2008.10.041","article-title":"Acetyl-L-carnitine provides effective in\u00a0vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain","volume":"158","author":"Alves","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00702-013-1149-z","article-title":"A\u00a0further update on the role of excitotoxicity in thepathogenesis of Parkinson\u2019s disease","volume":"121","author":"Ambrosi","year":"2014","journal-title":"J.\u00a0Neural Transm. (Vienna)"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/070674371405901003","article-title":"The role of untreated psychosis in neurodegeneration: a review of hypothesized mechanisms of neurotoxicity in first-episode psychosis","volume":"59","author":"Anderson","year":"2014","journal-title":"Can. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp.73.1.62","article-title":"Association study of three polymorphisms of TGF-beta1 gene with Alzheimer\u2019s disease","volume":"73","author":"Araria-Goumidi","year":"2002","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2005.09.010","article-title":"Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson\u2019s disease","volume":"22","author":"Armentero","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.04.044_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.mad.2007.07.006","article-title":"+10 T\/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution","volume":"128","author":"Arosio","year":"2007","journal-title":"Mech. Ageing Dev."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.04.044_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjp.0703904","article-title":"Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges","volume":"132","author":"Attucci","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/pr.111.005108","article-title":"Brain-derived neurotrophic factor and neuropsychiatric disorders","volume":"64","author":"Autry","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"21","key":"10.1016\/j.neuropharm.2016.04.044_bib12","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1523\/JNEUROSCI.20-21-07871.2000","article-title":"Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus","volume":"20","author":"Awad","year":"2000","journal-title":"J.\u00a0Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00213-005-2211-9","article-title":"The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison","volume":"179","author":"Ballard","year":"2005","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib14","first-page":"1605","article-title":"Levodopa-induced dyskinesias in Parkinson\u2019s disease: emerging treatments","volume":"9","author":"Bargiotas","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"12","key":"10.1016\/j.neuropharm.2016.04.044_bib15","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1002\/jnr.21722","article-title":"Hypoxia-induced deactivation of NGF-mediated ERK1\/2 signaling in hippocampal cells: neuroprotection by acetyl-L-carnitine","volume":"86","author":"Barhwal","year":"2008","journal-title":"J.\u00a0Neurosci. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib16","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1523\/JNEUROSCI.22-06-02135.2002","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity","volume":"22","author":"Battaglia","year":"2002","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0028-3908(03)00146-1","article-title":"Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice","volume":"45","author":"Battaglia","year":"2003","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.04.044_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1523\/JNEUROSCI.3831-03.2004","article-title":"Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice","volume":"24","author":"Battaglia","year":"2004","journal-title":"J.\u00a0Neurosci."},{"issue":"27","key":"10.1016\/j.neuropharm.2016.04.044_bib19","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1523\/JNEUROSCI.1595-06.2006","article-title":"Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"26","author":"Battaglia","year":"2006","journal-title":"J.\u00a0Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.04.044_bib20","doi-asserted-by":"crossref","first-page":"e6591","DOI":"10.1371\/journal.pone.0006591","article-title":"Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons","volume":"4","author":"Battaglia","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.11.012","article-title":"Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis","volume":"74","author":"Battaglia","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2015.07.017","article-title":"The GABA system in schizophrenia: cells, molecules and microcircuitry","volume":"167","author":"Benes","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neuropharm.2012.03.022","article-title":"Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson\u2019s disease treatment and dyskinesia","volume":"66","author":"Bennouar","year":"2013","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2016.04.044_bib24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.euroneuro.2012.11.013","article-title":"L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine","volume":"23","author":"Bersani","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pnpbp.2014.12.002","article-title":"Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory","volume":"58","author":"B\u00e9try","year":"2015","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib26","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/j.1476-5381.2012.01943.x","article-title":"Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson\u2019s disease","volume":"166","author":"Betts","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.schres.2005.04.001","article-title":"Association between the polymorphic GRM3 gene and negative symptom improvement during olanza- pine treatment","volume":"77","author":"Bishop","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/YPG.0b013e3281ac231e","article-title":"Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia","volume":"17","author":"Bishop","year":"2007","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hup.1163","article-title":"Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia","volume":"26","author":"Bishop","year":"2011","journal-title":"Hum. Psychopharm. Col."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neulet.2010.09.043","article-title":"Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"486","author":"Black","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1389202911314020007","article-title":"Role of the transforming-growth-factor-\u03b21 gene in late-onset Alzheimer\u2019s disease: implications for the treatment","volume":"14","author":"Bosco","year":"2013","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib32","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1523\/JNEUROSCI.22-13-05669.2002","article-title":"Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism","volume":"22","author":"Breysse","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib33","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1523\/JNEUROSCI.23-23-08302.2003","article-title":"Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats","volume":"23","author":"Breysse","year":"2003","journal-title":"J.\u00a0Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib34","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1523\/JNEUROSCI.17-06-01891.1997","article-title":"The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling","volume":"17","author":"Bruno","year":"1997","journal-title":"J.\u00a0Neurosci."},{"issue":"23","key":"10.1016\/j.neuropharm.2016.04.044_bib35","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1523\/JNEUROSCI.18-23-09594.1998","article-title":"Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta","volume":"18","author":"Bruno","year":"1998","journal-title":"J.\u00a0Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.04.044_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00004647-200109000-00001","article-title":"Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs","volume":"21","author":"Bruno","year":"2001","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.yco.0000194371.47685.f2","article-title":"An update on regional brain volume differences associated with mood disorders","volume":"19","author":"Campbell","year":"2006","journal-title":"Curr. Opin. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.04.044_bib38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1176\/appi.ajp.161.4.598","article-title":"Lower hippocampal volume in patients suffering from depression: a meta-analysis","volume":"161","author":"Campbell","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib39","first-page":"88","article-title":"Effect of MPEP in Morris water maze in adult and old rats","volume":"59","author":"Car","year":"2007","journal-title":"Pharmacol. Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.04.044_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"Caraci","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.04.044_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.euroneuro.2011.08.006","article-title":"The CC genotype of transforming growth factor-\u03b21 increases the risk of late-onset Alzheimer\u2019s disease and is associated with AD-related depression","volume":"22","author":"Caraci","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib42","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.1038\/srep11252","article-title":"A\u00a0key role for TGF-\u00e21 in hippocampal synaptic plasticity and memory","volume":"5","author":"Caraci","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib44","doi-asserted-by":"crossref","first-page":"457e467","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuropharm.2012.05.022","article-title":"mGlu2\/3 and mGlu5 receptors: potential targets for novel antidepressants","volume":"66","author":"Chaki","year":"2013","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00702-012-0850-7","article-title":"Meta-analysis of the transforming growth factor-\u03b21 polymorphisms and susceptibility to Alzheimer\u2019s disease","volume":"120","author":"Chang","year":"2013","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.schres.2004.07.002","article-title":"A\u00a0case- control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population","volume":"73","author":"Chen","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib48","doi-asserted-by":"crossref","first-page":"e0116549","DOI":"10.1371\/journal.pone.0116549","article-title":"Protection of TGF-\u03b21 against neuroinflammation and neurodegeneration in A\u03b21-42-induced Alzheimer\u2019s disease model rats","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib239","doi-asserted-by":"crossref","first-page":"26377","DOI":"10.1074\/jbc.M110.145516","article-title":"Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues","volume":"285","author":"Chen","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbr.2008.03.032","article-title":"MGlu5 antagonism impairs exploration and memory of spatial and non-spatial stimuli in rats","volume":"191","author":"Christoffersen","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.04.044_bib50","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2009.12.018","article-title":"Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation","volume":"67","author":"Cippitelli","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2016.04.044_bib240","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1353-8020(09)70782-5","article-title":"Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia","volume":"15","author":"Cenci","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2016.04.044_bib241","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S1353-8020(08)70014-2","article-title":"L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment","volume":"13","author":"Cenci","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib242","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fneur.2014.00049","article-title":"Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology","volume":"5","author":"Cerasa","year":"2014","journal-title":"Front Neurol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib243","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/molecules16032097","article-title":"Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders","volume":"16","author":"Cleva","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.npp.1300444","article-title":"Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats","volume":"29","author":"Coccurello","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bmcl.2015.11.098","article-title":"Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia","volume":"26","author":"Conde-Ceide","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.04.044_bib53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"31","key":"10.1016\/j.neuropharm.2016.04.044_bib54","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1523\/JNEUROSCI.1889-07.2007","article-title":"The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration\/neuroprotection","volume":"27","author":"Corti","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib55","doi-asserted-by":"crossref","first-page":"747e755","DOI":"10.1016\/j.biopsych.2006.12.005","article-title":"Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia","volume":"62","author":"Corti","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1100\/tsw.2007.47","article-title":"Neurodegeneration in schizophrenia: evidence from in\u00a0vivo neuroimaging studies","volume":"7","author":"Csernansky","year":"2007","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib57","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/npp.2013.121","article-title":"Upregulation of mGlu2 receptors via NF-jB p65 acetylation is involved in the proneurogenic and antidepressant effects of acetyl-L-carnitine","volume":"38","author":"Cuccurazzu","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib58","first-page":"10","article-title":"GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson\u2019s disease","volume":"9","author":"d\u2019Anglemont de Tassigny","year":"2015","journal-title":"Front. Neuroanat."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.04.044_bib59","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI30284","article-title":"Dysfunction of TGF-beta signaling in Alzheimer\u2019s disease","volume":"116","author":"Das","year":"2006","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuropharm.2013.02.005","article-title":"The two faces of the pharmacological interaction of mGlu2 and 5-HT\u2082A - relevance of receptor heterocomplexes and interaction through functional brain pathways","volume":"70","author":"Delille","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.04.044_bib61","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.neuroscience.2009.11.012","article-title":"Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain","volume":"165","author":"Di Liberto","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib244","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.neuropharm.2011.05.006","article-title":"mGluR2\/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1\/2 in mouse striatum","volume":"61","author":"Di Liberto","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib62","first-page":"10","article-title":"Functional cross-talk between group-I and group-II metabotropic glutamate receptors in heterologous expression systems and brain tissue","volume":"119","author":"Di Menna","year":"2015","journal-title":"Soc. Neurosci. Abs"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ajmg.b.30218","article-title":"Association studies of transforming growth factor-beta 1 and Alzheimer\u2019s disease","volume":"139B","author":"Dickson","year":"2005","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0028-3908(97)00001-4","article-title":"(RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus","volume":"36","author":"Doherty","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib65","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awm184","article-title":"Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia","volume":"130","author":"Douaud","year":"2007","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1096\/fj.10-163147","article-title":"A\u00a0new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors","volume":"25","author":"Doumazane","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib67","doi-asserted-by":"crossref","first-page":"93e118","DOI":"10.1007\/s00429-008-0189-x","article-title":"Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression","volume":"213","author":"Drevets","year":"2008","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuropharm.2013.11.015","article-title":"Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor protein cleavage","volume":"79","author":"Durand","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib69","doi-asserted-by":"crossref","first-page":"12604","DOI":"10.1073\/pnas.0405077101","article-title":"Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia","volume":"101","author":"Egan","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib70","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.ddtec.2012.10.007","article-title":"Allosteric modulation of class C GPCRs: a novel approach for the treatment of CNS disorders","volume":"10","author":"Engers","year":"2013","journal-title":"Drug Discov. Today Technol."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib71","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/mp.2015.35","article-title":"Kraepelin revisited: schizophrenia from degeneration to failed regeneration","volume":"20","author":"Falkai","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib72","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrn2649","article-title":"Psychobiology and molecular genetics of resilience","volume":"10","author":"Feder","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.04.044_bib74","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.neuropharm.2011.06.007","article-title":"Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia","volume":"62","author":"Fell","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib75","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1523\/JNEUROSCI.2702-13.2014","article-title":"Mechanisms of dopamine D1 receptor-mediated ERK1\/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5","volume":"34","author":"Fieblinger","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib76","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.molmed.2011.08.004","article-title":"Targeting glutamate synapses in schizophrenia","volume":"17","author":"Field","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib77","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/tpj.2009.24","article-title":"Candidate-gene association analysis of response to risperidone in African-American and white patients with schizo- phrenia","volume":"9","author":"Fijal","year":"2009","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib78","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2174\/092986707781745550","article-title":"Noradrenaline in Parkinson\u2019s disease: from disease progression to current therapeutics","volume":"14","author":"Fornai","year":"2007","journal-title":"Curr. Med. Chem."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2016.04.044_bib245","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1353-8020(13)70008-7","article-title":"Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse","volume":"20","author":"Francardo","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"18","key":"10.1016\/j.neuropharm.2016.04.044_bib79","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib80","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib81","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01.ypg.0000056682.82896.b0","article-title":"Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia","volume":"13","author":"Fujii","year":"2003","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-6606-7-31","article-title":"Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes","volume":"7","author":"Fujioka","year":"2014","journal-title":"Mol. Brain."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib83","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/jnc.13162","article-title":"Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson\u2019s disease","volume":"134","author":"Fuzzati-Armentero","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib246","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.pnpbp.2010.07.030","article-title":"Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders","volume":"35","author":"Gardner","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"6571","key":"10.1016\/j.neuropharm.2016.04.044_bib84","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib85","first-page":"196028","article-title":"Metabotropic glutamate receptors for Parkinson\u2019s disease therapy","author":"Gasparini","year":"2013","journal-title":"Park. Dis."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.04.044_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0006-8993(94)90857-5","article-title":"(2S,1\u2019R,2\u2019R,3\u2019R)-2-(2,3-dicarboxycyclopropyl) glycine positively modulates metabotropic glutamate receptors coupled to polyphosphoinositide hydrolysis in rat hippocampal slices","volume":"659","author":"Genazzani","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib88","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","article-title":"Alzheimer disease therapy\u2013moving from amyloid-\u03b2 to tau","volume":"9","author":"Giacobini","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib89","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fncel.2015.00297","article-title":"Monomeric \u03b2-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons","volume":"9","author":"Giuffrida","year":"2015","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib90","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2012.08.001","volume":"64","author":"Goeldner","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib91","doi-asserted-by":"crossref","first-page":"950e957","DOI":"10.1093\/schbul\/sbs010","article-title":"NMDA receptor hypofunction, parvalbumin- positive neurons, and cortical gamma oscillations in schizophrenia","volume":"38","author":"Gonzalez-Burgos","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib92","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biopsych.2015.03.010","article-title":"Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia","volume":"77","author":"Gonzalez-Burgos","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"410","key":"10.1016\/j.neuropharm.2016.04.044_bib93","doi-asserted-by":"crossref","first-page":"ra5","DOI":"10.1126\/scisignal.aab0467","article-title":"Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia","volume":"9","author":"Gonz\u00e1lez-Maeso","year":"2016","journal-title":"Sci. Signal"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib94","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib95","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys","volume":"17","author":"Gregoire","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib96","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","article-title":"Epigenetic GABAergic targets in schizophrenia and bipolar disorder","volume":"60","author":"Guidotti","year":"2011","journal-title":"Neuropharmacology"},{"issue":"41","key":"10.1016\/j.neuropharm.2016.04.044_bib97","doi-asserted-by":"crossref","first-page":"28460","DOI":"10.1074\/jbc.M114.584342","article-title":"Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5)","volume":"289","author":"Haas","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib98","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-6606-7-40","article-title":"Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer\u2019s disease","volume":"7","author":"Hamilton","year":"2014","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.09.041","article-title":"GABAergic mechanisms of hippocampal hyperactivity in schizophrenia","volume":"167","author":"Heckers","year":"2015","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","article-title":"Immune attack: the role of inflammation in Alzheimer disease","volume":"16","author":"Heppner","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.04.044_bib101","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.neuropharm.2004.01.018","article-title":"Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent","volume":"46","author":"Higgins","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib102","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.114.218651","article-title":"Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor","volume":"351","author":"Hiyoshi","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2007.08.001","article-title":"MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms","volume":"96","author":"Ho","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib247","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1523\/JNEUROSCI.2331-12.2013","article-title":"Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system","volume":"33","author":"Holloway","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib104","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.04.044_bib105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hipo.20934","article-title":"Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1\/2-Nrf2-regulated mitochondrial biosynthesis","volume":"22","author":"Hota","year":"2012","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pbb.2012.03.022","article-title":"Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson\u2019s disease rat model","volume":"102","author":"Hsieh","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib107","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2012.12.018","article-title":"Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings","volume":"144","author":"Hu","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12640-012-9348-1","article-title":"Neuroinflammation, neurodegeneration, and depression","volume":"23","author":"Hurley","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib110","article-title":"Biology of GDNF and its receptors \u2013 relevance for disorders of the central nervous system","author":"Ib\u00e1\u00f1ez","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib111","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.010909.105851","article-title":"Schizophrenia: treatment targets beyond monoamine systems","volume":"51","author":"Ibrahim","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib112","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2013.09.003","article-title":"Modulating mGluR5 and 5-HT1A\/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action","volume":"250","author":"Iderberg","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2015.02.023","article-title":"Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson\u2019s disease and L-DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist","volume":"95","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib114","first-page":"116","article-title":"Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia","volume":"27","author":"Jiang","year":"2013","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib115","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol- 4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib248","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrneurol.2015.249","article-title":"Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD","volume":"12","author":"Kalia","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.04.044_bib117","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.112.078501","article-title":"Functional and pharmacological characteristics of metabotropic glutamate receptors 2\/4 heterodimers","volume":"82","author":"Kammermeier","year":"2012","journal-title":"Mol. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.04.044_bib118","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1523\/JNEUROSCI.5643-07.2008","article-title":"Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra","volume":"28","author":"Kaushal","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib249","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2016.01.008","article-title":"Neuropathological relationship between major depression and dementia: A hypothetical model and review","volume":"67","author":"Kim","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.neuropharm.2016.04.044_bib119","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1523\/JNEUROSCI.4717-09.2010","article-title":"Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer\u2019s amyloid(beta)42 from isolated intact nerve terminals","volume":"30","author":"Kim","year":"2014","journal-title":"J.\u00a0Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.04.044_bib120","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/mp.2014.87","article-title":"Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer A\u03b2 oligomer mouse","volume":"19","author":"Kim","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib250","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1523\/JNEUROSCI.4717-09.2010","article-title":"Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals","volume":"30","author":"Kim","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib121","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/jpet.104.079244","article-title":"A\u00a0novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in\u00a0vivo activity and antipsychotic-like effects in rat behavioral models","volume":"13","author":"Kinney","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib122","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuropharm.2013.04.041","article-title":"Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment","volume":"72","author":"Kjaerby","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib124","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/schbul\/sbu070","article-title":"Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage","volume":"40","author":"Kochunov","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"7215","key":"10.1016\/j.neuropharm.2016.04.044_bib125","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature07455","article-title":"The molecular neurobiology of depression","volume":"455","author":"Krishnan","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neuropharm.2016.04.044_bib126","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.2009.10030434","article-title":"Linking molecules to mood: new insight into the biology of depression","volume":"167","author":"Krishnan","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib127","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic anti-depressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fnins.2015.00215","article-title":"Therapeutic potential of mGluR5 targeting in Alzheimer\u2019s disease","volume":"9","author":"Kumar","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbr.2014.03.008","article-title":"mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests","volume":"266","author":"Lainiola","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"18","key":"10.1016\/j.neuropharm.2016.04.044_bib130","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182364a44","article-title":"Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"issue":"7233","key":"10.1016\/j.neuropharm.2016.04.044_bib131","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nature07761","article-title":"Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers","volume":"457","author":"Laur\u00e9n","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib132","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.biopsych.2006.12.003","article-title":"Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex","volume":"62","author":"Lecourtier","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.04.044_bib133","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00401-004-0820-8","article-title":"Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer\u2019s disease","volume":"107","author":"Lee","year":"2004","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.04.044_bib134","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1021\/cn500340j","article-title":"Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: a review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine","volume":"6","author":"Leiser","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"1 Suppl.\u00a088","key":"10.1016\/j.neuropharm.2016.04.044_bib135","first-page":"S82","article-title":"A\u00a0randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data","volume":"33","author":"Leombruni","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib251","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuroimage.2009.11.021","article-title":"Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study","volume":"50","author":"Li","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib138","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.114.222463","article-title":"Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression","volume":"353","author":"Lindemann","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib139","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00018-015-2101-1","article-title":"Current disease modifying approaches to treat Parkinson\u2019s disease","volume":"73","author":"Lindholm","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.108.136580","article-title":"ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positiveallosteric modulator with preclinical antipsychotic-like and procognitive activities","volume":"327","author":"Liu","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib141","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuroscience.2012.08.010","article-title":"Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor","volume":"223","author":"Liu","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib142","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.npp.1300238","article-title":"Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge","volume":"28","author":"Lorrain","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib143","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s004390000313","article-title":"Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer\u2019s disease","volume":"106","author":"Luedecking","year":"2000","journal-title":"Hum. Genet."},{"issue":"16","key":"10.1016\/j.neuropharm.2016.04.044_bib144","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1523\/JNEUROSCI.21-16-05925.2001","article-title":"Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function","volume":"21","author":"Mannaioni","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib145","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1073\/pnas.1835724100","article-title":"Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson\u2019s disease treatment","volume":"100","author":"Marino","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib252","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","article-title":"Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex","volume":"292","author":"Marek","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"Pt 7","key":"10.1016\/j.neuropharm.2016.04.044_bib146","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/brain\/awr137","article-title":"Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys","volume":"134","author":"Masilamoni","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib147","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/npp.2011.274","article-title":"Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice","volume":"37","author":"Matrisciano","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib148","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/nn.4086","article-title":"Mechanisms of stress in the brain","volume":"18","author":"McEwen","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib149","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson\u2019s disease","volume":"101","author":"Mela","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1568026611313010005","article-title":"Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks","volume":"13","author":"Menniti","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib151","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"28","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib152","first-page":"4","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuro Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib153","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib154","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nlm.2015.03.005","article-title":"Interneuron epigenomes during the critical period of cortical plasticity: implications for schizophrenia","volume":"124","author":"Morishita","year":"2015","journal-title":"Neurobiol. Learn Mem."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13041-015-0158-2","article-title":"Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage","volume":"8","author":"Motolese","year":"2015","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib156","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1083\/jcb.201110101","article-title":"Dynamic remodeling of scaffold interactions in dendritic spines controls synaptic excitability","volume":"198","author":"Moutin","year":"2012","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib158","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0091-3057(02)00842-0","article-title":"Evaluation of the mGluR2\/3 agonist LY379268 in rodent models of Parkinson\u2019s disease","volume":"73","author":"Murray","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib159","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","article-title":"Three dimensions of the amyloid hypothesis: time, space and \u2019wingmen\u2019","volume":"18","author":"Musiek","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib160","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1073\/pnas.1216100110","article-title":"L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors","volume":"110","author":"Nasca","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib161","first-page":"1","article-title":"Mind the gap: glucocorticoids modulate hippocampal glutamate tone underlying individual differences in stress susceptibility","author":"Nasca","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib162","doi-asserted-by":"crossref","first-page":"14960","DOI":"10.1073\/pnas.1516016112","article-title":"Stress dynamically regulates behavior and glutamatergic gene expression in hippocampus by opening a window of epigenetic plasticity","volume":"112","author":"Nasca","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib163","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nbd.2013.09.013","article-title":"Development of allosteric modulators of GPCRs for treatment of CNS disorders","volume":"61","author":"Nickols","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.04.044_bib164","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0166-2236(96)20019-0","article-title":"Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?","volume":"19","author":"Nicoletti","year":"1996","journal-title":"Trends Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.04.044_bib165","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0028-3908(99)00102-1","article-title":"Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection","volume":"38","author":"Nicoletti","year":"1999","journal-title":"Neuropharmacology"},{"issue":"7\u20138","key":"10.1016\/j.neuropharm.2016.04.044_bib166","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib167","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coph.2014.12.002","article-title":"Metabotropic glutamate receptors as drug targets: what\u2019s new?","volume":"20","author":"Nicoletti","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib168","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib169","first-page":"335","article-title":"Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling","volume":"14","author":"Noetzel","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib170","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1124\/mol.112.082891","article-title":"A\u00a0novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling","volume":"83","author":"Noetzel","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib171","first-page":"5","article-title":"No evidence for association between polymorphisms in GRM3 and schizo- phrenia","volume":"13","author":"Norton","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib172","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neubiorev.2014.12.016","article-title":"A\u00a0role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review","volume":"51","author":"Notaras","year":"2015","journal-title":"Neurosci. Biobehav Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib173","doi-asserted-by":"crossref","first-page":"61","DOI":"10.9758\/cpn.2012.10.2.61","article-title":"Review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia","volume":"10","author":"Nurjono","year":"2012","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib174","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib175","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1111\/j.1460-9568.2005.04498.x","article-title":"Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism","volume":"22","author":"Oueslati","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib176","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuropharm.2012.12.003","article-title":"Mechanism based neurotoxicity of mGlu5 positive allosteric modulators\u2013development challenges for a promising novel antipsychotic target","volume":"82","author":"Parmentier-Batteur","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib177","doi-asserted-by":"crossref","first-page":"17365","DOI":"10.1523\/JNEUROSCI.2904-12.2012","article-title":"Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset","volume":"32","author":"Pasternak","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib178","article-title":"In\u00a0vivo imaging of neuroinflammation in schizophrenia","author":"Pasternak","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib179","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2014.07.031","article-title":"The extent of diffusion MRI markers of neuroinflammation and white matter deterioration in chronic schizophrenia","volume":"161","author":"Pasternak","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuroscience.2012.03.006","article-title":"Acetyl-L-carnitine treatment following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery","volume":"210","author":"Patel","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib181","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2014.07.044","article-title":"Treatment of cognitive dysfunction in major depressive disorder\u2014a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin\u2013norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine","volume":"753","author":"Patil","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib253","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2014.07.044","article-title":"Treatment of cognitive dysfunction in major depressive disorder\u2013a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin\u2013norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine","volume":"753","author":"Pehrson","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib182","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11064-006-9162-3","article-title":"Possible mechanisms of neurodegeneration in schizophrenia","volume":"31","author":"P\u00e9rez-Neri","year":"2006","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib183","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0091-3057(02)00829-8","article-title":"Differential effects of mGluR1 and mGluR5 antagonism on spatial learning in rats","volume":"73","author":"Petersen","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.04.044_bib184","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.neuropharm.2006.01.002","article-title":"Acetyl-L-carnitine protects striatal neurons against in\u00a0vitro ischemia: the role of endogenous acetylcholine","volume":"50","author":"Picconi","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0028-3908(02)00082-5","article-title":"Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats","volume":"43","author":"Pilc","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib186","doi-asserted-by":"crossref","first-page":"997e1006","DOI":"10.1016\/j.bcp.2007.09.021","article-title":"Mood disorders: regulation by metabotropic glutamate receptors","volume":"75","author":"Pilc","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.04.044_bib187","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0306-4522(01)00297-4","article-title":"Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons","volume":"106","author":"Pisani","year":"2001","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib188","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neuropharm.2011.01.051","article-title":"Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of \u03b2-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices","volume":"60","author":"Rammes","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib189","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pharmtox.010909.105800","article-title":"Molecular mechanism of \u03b2-arrestin-biased agonism at seven-transmembrane receptors","volume":"52","author":"Reiter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib191","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib192","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neuron.2010.04.029","article-title":"Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5","volume":"66","author":"Renner","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib254","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.brainres.2010.09.072","article-title":"Altered distribution of mGlu2 receptors in \u03b2-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice","volume":"1363","author":"Richards","year":"2010","journal-title":"Brain Res."},{"issue":"171C","key":"10.1016\/j.neuropharm.2016.04.044_bib193","first-page":"85","article-title":"Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study","volume":"28","author":"Roca","year":"2014","journal-title":"J.\u00a0Affect. Disord. Sep."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib194","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/mol.110.067207","article-title":"Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in\u00a0vivo activity in rat behavioral models of anxiolytic and antipsychotic activity","volume":"78","author":"Rodriguez","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-0404.2007.00892.x","article-title":"Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer\u2019s disease","volume":"116","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib196","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2010.08.009","article-title":"The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein-coupled receptors","volume":"60","author":"Rondard","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib197","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.biopsych.2012.09.012","article-title":"Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in\u00a0vivo activity","volume":"73","author":"Rook","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib198","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuron.2015.03.063","article-title":"Biased mGlu5-positive allosteric modulators provide in\u00a0vivo efficacy without potentiating mGlu5 modulation of NMDAR currents","volume":"86","author":"Rook","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib199","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.euroneuro.2013.05.008","article-title":"Autoimmune-induced glutamatergic receptor dysfunctions: conceptual and psychiatric practice implications","volume":"23","author":"Rosenthal-Simons","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib201","doi-asserted-by":"crossref","first-page":"2643e2651","DOI":"10.1016\/j.neuroimage.2010.11.011","article-title":"Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder","volume":"54","author":"Salvadore","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib202","first-page":"2626","article-title":"Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP","volume":"33","author":"Sartorius","year":"2008","journal-title":"Neuro Psychopharmacol."},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2016.04.044_bib203","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000323178","article-title":"Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain","volume":"32","author":"Scafidi","year":"2010","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib204","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2009.09.006","article-title":"Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2\/3) receptor agonist LY354740 in tests for antipsychotic-like activity","volume":"623","author":"Schlumberger","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib205","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1046\/j.1471-4159.1996.66051981.x","article-title":"(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced increases in cyclic AMP formation in the neonatal rat hippocampus are mediated by a synergistic interaction between phosphoinositide- and inhibitory cyclic AMP-coupled mGluRs","volume":"66","author":"Schoepp","year":"1996","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/YPG.0b013e3282ef48d9","article-title":"DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study","volume":"18","author":"Schwab","year":"2008","journal-title":"Psychiatr. Genet."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.04.044_bib207","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2460","article-title":"Resolving controversies on the path to Alzheimer\u2019s therapeutics","volume":"17","author":"Selkoe","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nlm.2016.01.004","article-title":"Acute inhibition of mGluR5 disrupts behavioral flexibility","volume":"130","author":"Sethna","year":"2016","journal-title":"Neurobiol. Learn Mem."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib209","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.neubiorev.2011.12.015","article-title":"Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia","volume":"36","author":"Shepherd","year":"2012","journal-title":"Neurosci. Biobehav Rev."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/alzrt209","article-title":"Progress in novel cognitive enhancers for cognitive aging and Alzheimer\u2019s disease","volume":"5","author":"Shineman","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib255","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0b013e3182166dc7","article-title":"Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links","volume":"76","author":"Sokol","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib211","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0006-3223(02)01393-8","article-title":"Smaller frontal lobe white matter volumes in depressed adolescents","volume":"52","author":"Steingard","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2016.04.044_bib212","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.biopsych.2004.08.022","article-title":"Cellular changes in the postmortem hippocampus in major depression","volume":"56","author":"Stockmeier","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib213","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4001563","article-title":"Phenotype of schizophrenia: a review and formulation","volume":"10","author":"Tamminga","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib214","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1046\/j.1471-4159.2002.01062.x","article-title":"Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer\u2019s disease","volume":"82","author":"Taylor","year":"2002","journal-title":"J.\u00a0Neurochem."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.04.044_bib215","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1523\/JNEUROSCI.4456-04.2005","article-title":"Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand","volume":"25","author":"Taylor","year":"2005","journal-title":"J.\u00a0Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.04.044_bib216","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1172\/JCI27341","article-title":"Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer\u2019s pathology","volume":"116","author":"Tesseur","year":"2006","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib217","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.bp.106.033670","article-title":"Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia","volume":"191","author":"Th\u00e9berge","year":"2007","journal-title":"Br. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.neuropharm.2016.04.044_bib218","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/jnr.23082","article-title":"Transforming growth factor-\u03b2 stimulates \u03b2 amyloid uptake by microglia through Smad3-dependent mechanisms","volume":"90","author":"Tichauer","year":"2012","journal-title":"J.\u00a0Neurosci. Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.04.044_bib219","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(00)80810-7","article-title":"Coupling of mGluR\/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins","volume":"23","author":"Tu","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00213-005-2202-x","article-title":"Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson\u2019s disease","volume":"179","author":"Turle-Lorenzo","year":"2005","journal-title":"Psychopharmacol. Berl."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.04.044_bib221","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0028-3908(97)00103-2","article-title":"Potentiation of NMDA and AMPA responses by group I mGluR in spinal cord motoneurons","volume":"36","author":"Ugolini","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib222","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrn2774","article-title":"Abnormal neural oscillations and synchrony in schizophrenia","volume":"11","author":"Uhlhaas","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.04.044_bib223","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","article-title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u03b2 oligomer bound to cellular prion protein","volume":"79","author":"Um","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib224","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1523\/JNEUROSCI.23-18-07218.2003","article-title":"Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse","volume":"23","author":"Valenti","year":"2003","journal-title":"J.\u00a0Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.04.044_bib225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neulet.2006.03.050","article-title":"Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene and risk of dementia. The Rotterdam Study","volume":"402","author":"van Oijen","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.04.044_bib226","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jad.2007.11.011","article-title":"Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study","volume":"109","author":"Vasic","year":"2008","journal-title":"J.\u00a0Affect Disord."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.04.044_bib227","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1503\/jpn.140246","article-title":"Baseline brain perfusion and brain structure in patients with major depression: a multimodal magnetic resonance imaging study","volume":"40","author":"Vasic","year":"2015","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib228","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.neuropharm.2011.05.005","article-title":"Metabotropic glutamate receptors as therapeutic targets for schizophrenia","volume":"262","author":"Vinson","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib229","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuroscience.2013.06.008","article-title":"Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia","volume":"248","author":"Volk","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.04.044_bib230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coph.2014.11.003","article-title":"Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics","volume":"20","author":"Walker","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib231","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jpsychires.2014.02.005","article-title":"A\u00a0review of current evidence for acetyl-l-carnitine in the treatment of depression","volume":"53","author":"Wang","year":"2014","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib232","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuroscience.2014.11.025","article-title":"Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K\/AKT\/BDNF\/VGF signaling pathway in mice","volume":"285","author":"Wang","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.04.044_bib233","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1523\/JNEUROSCI.1129-13.2014","article-title":"Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS","volume":"34","author":"Yin","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib234","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.euroneuro.2005.10.005","article-title":"A\u00a0double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia","volume":"16","author":"Zanardi","year":"2006","journal-title":"Eur. Neuro Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.04.044_bib235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1196\/annals.1344.013","article-title":"Mechanisms of ischemic neuroprotection by acetyl-L-carnitine","volume":"1053","author":"Zanelli","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib236","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3390\/ijms13022078","article-title":"Neuroprotective effects of pre-treatment with l-carnitine and acetyl-L-carnitine on ischemic injury in\u00a0vivo and in\u00a0vitro","volume":"13","author":"Zhang","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"39","key":"10.1016\/j.neuropharm.2016.04.044_bib237","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1523\/JNEUROSCI.1034-15.2015","article-title":"Neuronal store-operated calcium entry and mushroom spine loss in amyloid precursor protein knock-in mouse model of alzheimer\u2019s disease","volume":"35","author":"Zhang","year":"2015","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.04.044_bib238","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.biopsych.2009.09.014","article-title":"Changes of brain morphometry in first-episode, drug-na\u00efve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study","volume":"67","author":"Zou","year":"2010","journal-title":"Biol. Psychiatry"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816301848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816301848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:37:06Z","timestamp":1748907426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816301848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":249,"alternative-id":["S0028390816301848"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.04.044","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of metabotropic glutamate receptors into active neurodegenerative processes: A \u201cdark side\u201d in the development of new symptomatic treatments for neurologic and psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}